CMS Open Payments · Program Year 2024
Blue Sky Bio, LLC
Blue Sky Bio, LLC reported $8,658,422.00 across General Payments, Research, and Ownership to 48 physicians and teaching hospitals across 50 transactions.
- $8.7M Top 10% payer
- All-tracks total
- 50 Below-median volume
- Transactions
- 48 Below-median reach
- Recipients
- +$31.8K
- General Payments vs PY2023
Blue Sky Bio, LLC reported $8,658,422.00 across all CMS Open Payments tracks (General + Research + Ownership) to 48 physicians and teaching hospitals in Program Year 2024 - ranking #193 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $314,197.00, averaging $180.4K per recipient.
How Blue Sky Bio, LLC's $8.7M all-tracks total breaks down
Blue Sky Bio, LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
30/100
Total payments
A
90/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer blue-sky-bio-llc Blue Sky Bio, LLC
$8.7M · #193/1,925 · 0.1% industry · PY2024
- TOT $8.7M
- RANK #193
- SHARE 0.1%
- TXN 50
- RCP 48
- CAT 1
- GEN $314.2K
- ΔGEN +$31.8K
- TOP1 38.2%
- PY 2024
Volume peers
Nearest volume peer: Contego Medical, Inc ($8.7M)
Blue Sky Bio, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Blue Sky Bio, LLC's CMS-reported General Payments increased by $31.8K (+11.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: BLUE SKY BIO, LLCPY2023: BLUE SKY BIO, LLCPY2024: Blue Sky Bio, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $282,400.00
- PY2024
- $314,197.00
What the Data Shows for Blue Sky Bio, LLC
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Blue Sky Bio, LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Consulting Fee" leads the 1-category general-payment breakdown below at $314.2K (100.0% of General Payments, 48 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 1 types of general payments, Blue Sky Bio, LLC's largest category was "Consulting Fee" at $314.2K - 100.0% of General Payments.
How Blue Sky Bio, LLC divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $314.2K | 48 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $314,197.00 (100.0%) of $314,197.00 in this company's General Payments records across 4 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Blue Sky Bio, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Nathan Cory Glenn
$120,000.00 across 12 reported transactions
- 2
Baron Grutter
$74,197.00 across 12 reported transactions
- 3
Robert Mikhli
$60,000.00 across 12 reported transactions
- 4
Marc Lipkin
$60,000.00 across 12 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Blue Sky Bio, LLC ranks #193 of 1,925 by total payments (top 10% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #606 of 1,838 by HHI (top 33% most concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Masimo Corporation : $2.6M total payments, HHI 2786
- Phadia AB : $11.9K total payments, HHI 2782
- Daiichi Sankyo Europe GmbH : $77.3K total payments, HHI 2769
- Pramand LLC : $22.8K total payments, HHI 2763
- Cleerly, Inc. : $157.5K total payments, HHI 2760
- Biodynamik, Inc : $23.6K total payments, HHI 2759
- Blue Sky Bio, LLC (this company) : $314.2K total payments, HHI 2746
- BTG International, Inc. : $670.8K total payments, HHI 2745
- Carbofix Orthopedics Inc : $49.7K total payments, HHI 2743
- Hyperfine Operations, Inc. : $52.4K total payments, HHI 2743
- 3NT Medical : $11.0K total payments, HHI 2735
- Boehringer Ingelheim Pharma GmbH & Co.KG : $27.7K total payments, HHI 2733
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Blue Sky Bio, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Blue Sky Bio, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Blue Sky Bio, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Si-Technology, LLC
Ignite Orthopedics, LLC
SpectraWAVE, Inc
Indivior Inc.
Shoulder Innovations, Inc.
Put this to use
Blue Sky Bio, LLC ranks #193 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Blue Sky Bio, LLC sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Blue Sky Bio, LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.